Free Trial

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group. Learn more about health care stocks.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$743.91 +6.08 (+0.82%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The current stock price is around $732, reflecting a strong market position and investor confidence in the company's growth potential.
  • Eli Lilly and Co reported impressive quarterly earnings, with earnings per share (EPS) significantly exceeding analyst expectations, indicating robust financial health.
  • The company has shown a remarkable year-over-year revenue growth of over 37%, suggesting strong demand for its products and effective business strategies.

Cons of Eli Lilly and Company

  • Insider ownership is relatively low at 0.14%, which may indicate a lack of confidence from those closest to the company.
  • The company's debt-to-equity ratio is 1.86, suggesting a higher reliance on debt financing, which can pose risks in economic downturns.
  • Recent stock price fluctuations indicate volatility, which could lead to potential losses for investors if market conditions change.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$704.31 billion
P/E Ratio
48.64
Consensus Rating
Moderate Buy
Consensus Price Target
$950.17 (+27.7% Upside)
Volume
1.80 million shares
Average Volume
4.14 million shares
Today's Range
$735.33
$747.00
50-Day Range
$625.15
$811.73
52-Week Range
$623.78
$943.00
Dividend Yield
0.82%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$178.84 +0.84 (+0.47%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The current stock price is around $177, reflecting a strong market position and investor confidence in the company's growth potential.
  • Johnson & Johnson has recently received multiple upgrades from analysts, including a "buy" rating from Erste Group Bank, indicating positive sentiment and potential for price appreciation.
  • The company reported a quarterly earnings per share (EPS) of $2.77, surpassing expectations, which demonstrates strong financial performance and operational efficiency.

Cons of Johnson & Johnson

  • Despite recent upgrades, the stock has a relatively high price-to-earnings (P/E) ratio of around 19, which may indicate that the stock is overvalued compared to its earnings potential.
  • The company has faced challenges in the past, including legal issues related to product safety, which could pose risks to its reputation and financial stability.
  • Johnson & Johnson's revenue growth, while positive, was only 5.8% year-over-year, which may not meet the expectations of aggressive growth investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$430.51 billion
P/E Ratio
19.12
Consensus Rating
Moderate Buy
Consensus Price Target
$176.29 (-1.4% Downside)
Volume
4.75 million shares
Average Volume
8.95 million shares
Today's Range
$177.55
$178.68
50-Day Range
$152.25
$179.10
52-Week Range
$140.68
$181.16
Dividend Yield
2.93%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$212.60 +0.74 (+0.35%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • The current stock price is around $210, reflecting a strong market position and investor interest.
  • AbbVie has shown a solid revenue growth of 6.6% year-over-year, indicating a positive trend in its financial performance.
  • The company has a high return on equity, suggesting effective management and profitability relative to shareholder equity.

Cons of AbbVie

  • The company recently missed earnings expectations, which could raise concerns about its short-term performance.
  • AbbVie has a relatively high price-to-earnings ratio, which may suggest that the stock is overvalued compared to its earnings.
  • There is a significant level of institutional ownership, which can lead to volatility if large investors decide to sell.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$375.58 billion
P/E Ratio
101.24
Consensus Rating
Moderate Buy
Consensus Price Target
$214.95 (+1.1% Upside)
Volume
1.66 million shares
Average Volume
6.52 million shares
Today's Range
$211.66
$214.19
50-Day Range
$181.89
$211.63
52-Week Range
$163.81
$218.66
Dividend Yield
3.12%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$310.10 +2.22 (+0.72%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The current stock price is around $309, which reflects a stable position in the market.
  • UnitedHealth Group has demonstrated strong revenue growth, with a year-over-year increase of 12.9% for the latest quarter, indicating robust business performance.
  • The company has a solid dividend yield of 2.9%, providing a reliable income stream for investors through its quarterly dividend payments.

Cons of UnitedHealth Group

  • Recent insider selling, including a notable transaction by the CEO, may raise concerns about the company's future prospects and management confidence.
  • Despite the revenue growth, the stock has shown a slight decline of 0.2% recently, which could indicate market volatility or investor uncertainty.
  • The company's debt-to-equity ratio of 0.73 suggests a moderate level of debt, which could impact financial stability in adverse market conditions.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$280.69 billion
P/E Ratio
13.43
Consensus Rating
Moderate Buy
Consensus Price Target
$353.71 (+14.1% Upside)
Volume
6.33 million shares
Average Volume
12.76 million shares
Today's Range
$304.10
$311.91
50-Day Range
$237.40
$325.83
52-Week Range
$234.60
$630.73
Dividend Yield
2.85%
Novartis stock logo

5. Novartis NYSE:NVS

$128.67 +0.44 (+0.34%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • Novartis AG recently reported earnings per share of $2.42, exceeding analysts' expectations, indicating strong financial performance and effective management.
  • The company achieved a revenue of $14.05 billion for the quarter, reflecting a 12.3% increase compared to the same quarter last year, showcasing robust growth.
  • Current stock price is around $126.56, which is near its 1-year high of $128.03, suggesting positive market sentiment and potential for further appreciation.

Cons of Novartis

  • Despite strong earnings, the stock has seen fluctuations, indicating potential volatility that could affect short-term investors.
  • Some analysts have issued "sell" ratings, reflecting concerns about market conditions or company-specific challenges that could impact future performance.
  • Institutional ownership is at 13.12%, which may suggest limited confidence from larger investors in the company's long-term prospects.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$271.81 billion
P/E Ratio
18.73
Consensus Rating
Hold
Consensus Price Target
$123.50 (-4.0% Downside)
Volume
1.03 million shares
Average Volume
1.92 million shares
Today's Range
$128.48
$129.21
50-Day Range
$113.55
$128.13
52-Week Range
$96.06
$129.21
Dividend Yield
2.05%
AstraZeneca stock logo

6. AstraZeneca NASDAQ:AZN

$81.82 -0.29 (-0.35%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More about AstraZeneca

Pros of AstraZeneca

  • The current stock price is around $80, reflecting a stable market position and potential for growth.
  • AstraZeneca has shown strong revenue growth, with a recent quarterly revenue increase of over 16% compared to the previous year, indicating robust demand for its products.
  • The company has a solid market capitalization of approximately $248 billion, suggesting a strong financial foundation and investor confidence.

Cons of AstraZeneca

  • The stock has experienced fluctuations, with a 52-week high of $87.68 and a low of $61.24, indicating volatility that may concern risk-averse investors.
  • AstraZeneca recently cut its dividend, which may signal financial caution and could deter income-focused investors.
  • The company's price-to-earnings (P/E) ratio is around 30, which may be considered high compared to industry averages, suggesting that the stock could be overvalued.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$253.74 billion
P/E Ratio
30.76
Consensus Rating
Moderate Buy
Consensus Price Target
$86.00 (+5.1% Upside)
Volume
2.38 million shares
Average Volume
5.19 million shares
Today's Range
$81.48
$82.28
50-Day Range
$68.72
$82.11
52-Week Range
$61.24
$84.30
Dividend Yield
1.26%
Novo Nordisk A/S stock logo

7. Novo Nordisk A/S NYSE:NVO

$56.30 -0.45 (-0.78%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $56, which may present a buying opportunity for investors looking for value.
  • Recent earnings reports show that Novo Nordisk has consistently exceeded analysts' expectations, indicating strong financial performance.
  • The company has a high return on equity, suggesting effective management and profitability, which can be attractive to investors.

Cons of Novo Nordisk A/S

  • The stock has experienced significant volatility, with a 52-week high of $139.74 and a low of $45.05, which may deter risk-averse investors.
  • Recent revenue figures have not met analysts' expectations, which could indicate potential challenges in maintaining growth.
  • The company's debt-to-equity ratio is moderate, suggesting that it may rely on debt financing, which can be a risk if market conditions change.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$251.50 billion
P/E Ratio
15.47
Consensus Rating
Hold
Consensus Price Target
$81.00 (+43.9% Upside)
Volume
7.02 million shares
Average Volume
11.71 million shares
Today's Range
$55.46
$56.50
50-Day Range
$45.31
$71.67
52-Week Range
$45.05
$138.22
Dividend Yield
1.46%
Abbott Laboratories stock logo

8. Abbott Laboratories NYSE:ABT

$132.56 +0.38 (+0.28%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $130.96, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Abbott Laboratories has recently seen significant institutional investment, with multiple funds increasing their holdings, indicating strong confidence in the company's future performance.
  • The company has a solid dividend yield of 1.8%, providing a steady income stream for investors, which is particularly attractive in uncertain market conditions.

Cons of Abbott Laboratories

  • The stock has recently experienced a decline of about 1.3%, which may indicate short-term volatility and uncertainty in the market.
  • Insider selling has been reported, with the CFO selling shares, which could raise concerns about the company's internal confidence and future outlook.
  • Despite strong institutional interest, 75.18% of the stock is held by institutional investors, which can lead to increased volatility if these investors decide to sell.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$230.86 billion
P/E Ratio
16.62
Consensus Rating
Moderate Buy
Consensus Price Target
$144.47 (+9.0% Upside)
Volume
3.23 million shares
Average Volume
6.71 million shares
Today's Range
$131.70
$133.84
50-Day Range
$120.76
$136.21
52-Week Range
$110.86
$141.23
Dividend Yield
1.78%
Merck & Co., Inc. stock logo

9. Merck & Co., Inc. NYSE:MRK

$83.96 -0.22 (-0.26%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck has seen significant institutional investment, with over 76% of its stock owned by institutional investors and hedge funds, indicating strong confidence in the company's future performance.
  • The current stock price is around $107.44, reflecting a consensus rating of "Hold" from analysts, suggesting stability and potential for growth.
  • Recent acquisitions by major investors, such as Magnetar Financial LLC and Adage Capital Partners GP L.L.C., demonstrate increasing interest and confidence in Merck's market position.

Cons of Merck & Co., Inc.

  • Recent downgrades in price targets by analysts, such as Citigroup and Wells Fargo, suggest that there may be concerns about Merck's short-term performance.
  • Some analysts have shifted their ratings to "cautious," indicating potential risks that could affect investor sentiment and stock performance.
  • Market volatility and economic uncertainties could impact Merck's stock price, making it a riskier investment in the current climate.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$209.61 billion
P/E Ratio
12.93
Consensus Rating
Hold
Consensus Price Target
$107.44 (+28.0% Upside)
Volume
8.19 million shares
Average Volume
15.20 million shares
Today's Range
$83.00
$84.41
50-Day Range
$78.17
$87.18
52-Week Range
$73.31
$120.30
Dividend Yield
3.85%
Thermo Fisher Scientific stock logo

10. Thermo Fisher Scientific NYSE:TMO

$489.73 +5.18 (+1.07%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The stock has received multiple "buy" ratings from analysts, indicating strong confidence in its future performance.
  • Recent price targets from analysts suggest significant upside potential, with consensus estimates around $593.00.
  • The current stock price is approximately $500, which may present a buying opportunity given the positive outlook from analysts.

Cons of Thermo Fisher Scientific

  • Insider selling activity has been noted, with significant shares sold by executives, which may raise concerns about their confidence in the company's future performance.
  • Some analysts have recently downgraded their ratings or reduced price targets, indicating potential volatility in the stock's performance.
  • The company faces competition in the life sciences sector, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$184.93 billion
P/E Ratio
28.32
Consensus Rating
Moderate Buy
Consensus Price Target
$589.38 (+20.3% Upside)
Volume
893,608 shares
Average Volume
2.42 million shares
Today's Range
$471.61
$489.64
50-Day Range
$405.15
$500.24
52-Week Range
$385.46
$627.88
Dividend Yield
0.35%
Intuitive Surgical stock logo

11. Intuitive Surgical NASDAQ:ISRG

$453.02 +11.84 (+2.68%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The current stock price is around $469, which may present a buying opportunity for investors looking for growth in the medical equipment sector.
  • Intuitive Surgical, Inc. reported strong earnings, with earnings per share exceeding expectations, indicating robust financial health and operational efficiency.
  • The company has demonstrated significant revenue growth, with a year-over-year increase of over 21%, showcasing its expanding market presence and demand for its products.

Cons of Intuitive Surgical

  • The stock has a high P/E ratio, which may suggest that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Intuitive Surgical, Inc. has a beta of 1.61, indicating higher volatility compared to the market, which could pose risks for conservative investors.
  • Recent institutional investments have shown mixed trends, which may indicate uncertainty among larger investors regarding the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$162.40 billion
P/E Ratio
63.18
Consensus Rating
Moderate Buy
Consensus Price Target
$595.95 (+31.6% Upside)
Volume
3.02 million shares
Average Volume
2.01 million shares
Today's Range
$437.41
$455.28
50-Day Range
$441.18
$543.74
52-Week Range
$425.00
$616.00
Dividend Yield
N/A
Boston Scientific stock logo

12. Boston Scientific NYSE:BSX

$106.66 -0.87 (-0.81%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • Boston Scientific Co. has received multiple "strong-buy" ratings from analysts, indicating strong confidence in the company's future performance.
  • The current stock price is around $106, reflecting a solid position in the market and potential for growth.
  • Recent upgrades in target prices by various financial institutions suggest a positive outlook, with some estimates reaching as high as $125.

Cons of Boston Scientific

  • Insider selling has been notable, with executives selling significant shares, which may raise concerns about their confidence in the company's future.
  • The stock has experienced fluctuations, with a 52-week low of around $79.53, indicating potential volatility that could affect investment returns.
  • The price-to-earnings (P/E) ratio is relatively high at around 63, suggesting that the stock may be overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$158.41 billion
P/E Ratio
63.64
Consensus Rating
Buy
Consensus Price Target
$117.50 (+10.2% Upside)
Volume
4.46 million shares
Average Volume
7.47 million shares
Today's Range
$107.08
$108.47
50-Day Range
$102.44
$107.51
52-Week Range
$80.50
$108.94
Dividend Yield
N/A
Amgen stock logo

13. Amgen NASDAQ:AMGN

$280.21 -3.64 (-1.28%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • The current stock price is around $287, which may present a buying opportunity for investors looking for value in the biotech sector.
  • Amgen Inc. has a strong market capitalization of approximately $154 billion, indicating a solid position in the industry and potential for growth.
  • Recent analyst ratings show a consensus rating of "Hold," with a price target averaging around $304.43, suggesting that analysts see potential for price appreciation.

Cons of Amgen

  • Recent downgrades from analysts, including a cut from "buy" to "hold," may indicate concerns about the company's short-term performance.
  • Insider selling activity, with senior vice presidents recently selling shares, could signal a lack of confidence in the company's near-term prospects.
  • The company's debt-to-equity ratio is relatively high at 7.24, which may raise concerns about financial stability and the ability to manage debt effectively.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$150.93 billion
P/E Ratio
22.92
Consensus Rating
Hold
Consensus Price Target
$304.43 (+8.6% Upside)
Volume
1.57 million shares
Average Volume
2.79 million shares
Today's Range
$278.75
$284.76
50-Day Range
$277.13
$309.22
52-Week Range
$253.30
$339.17
Dividend Yield
3.31%
Stryker stock logo

14. Stryker NYSE:SYK

$394.00 +5.44 (+1.40%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The current stock price is around $430, reflecting a strong market position and investor confidence in the company's growth potential.
  • Stryker Co. has a solid dividend payout ratio of 44.50%, indicating a commitment to returning value to shareholders while still reinvesting in the business.
  • Recent analyst ratings show a consensus of "Moderate Buy," with fifteen analysts recommending a buy, suggesting strong market support for the stock.

Cons of Stryker

  • Despite a strong market presence, the stock has shown volatility, which may deter risk-averse investors looking for stable returns.
  • Some analysts have set lower price targets, such as $415, indicating that not all market participants are optimistic about the stock's near-term performance.
  • The company's dividend yield is relatively low at 0.9%, which may not attract income-focused investors compared to other options in the market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$150.68 billion
P/E Ratio
52.20
Consensus Rating
Moderate Buy
Consensus Price Target
$430.10 (+9.2% Upside)
Volume
620,459 shares
Average Volume
1.41 million shares
Today's Range
$386.81
$396.86
50-Day Range
$374.93
$403.34
52-Week Range
$329.16
$406.19
Dividend Yield
0.86%
Danaher stock logo

15. Danaher NYSE:DHR

$198.94 -0.50 (-0.25%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The current stock price is around $206, which reflects a solid performance in the market and may present a buying opportunity for investors looking for growth.
  • Danaher Co. has a strong track record of beating earnings expectations, recently reporting earnings per share that exceeded analyst estimates, indicating robust operational performance.
  • With a market capitalization of approximately $147.57 billion, Danaher Co. is a significant player in its industry, suggesting stability and potential for continued growth.

Cons of Danaher

  • The stock has experienced significant volatility, with a 12-month high of $279.90 and a low of $171.00, indicating potential risks associated with price fluctuations.
  • Despite recent earnings growth, the company's high P/E ratio suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Recent insider selling activity may raise concerns about the confidence of company leadership in the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$142.39 billion
P/E Ratio
42.31
Consensus Rating
Moderate Buy
Consensus Price Target
$246.35 (+23.8% Upside)
Volume
2.30 million shares
Average Volume
4.15 million shares
Today's Range
$192.18
$199.79
50-Day Range
$188.23
$212.24
52-Week Range
$171.00
$279.90
Dividend Yield
0.62%
Gilead Sciences stock logo

16. Gilead Sciences NASDAQ:GILD

$112.71 -0.28 (-0.24%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • Recent upgrades from multiple analysts, including a strong-buy rating from Daiwa America, indicate growing confidence in the company's future performance.
  • The current stock price is around $112.71, which reflects a stable position in the market and potential for growth based on recent analyst ratings.
  • Gilead Sciences, Inc. has a market capitalization of approximately $139.85 billion, suggesting it is a significant player in the biopharmaceutical industry, which can provide stability to investors.

Cons of Gilead Sciences

  • Insiders have sold a significant number of shares recently, totaling 82,000 shares worth over $9 million, which may indicate a lack of confidence in the company's short-term prospects.
  • The company has a debt-to-equity ratio of 1.13, which suggests that it has a higher level of debt compared to its equity, potentially increasing financial risk for investors.
  • Despite recent upgrades, the stock has shown a slight decrease of 0.2%, which could signal volatility and uncertainty in the market.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$139.92 billion
P/E Ratio
22.46
Consensus Rating
Moderate Buy
Consensus Price Target
$115.39 (+2.4% Upside)
Volume
2.18 million shares
Average Volume
8.09 million shares
Today's Range
$112.28
$113.83
50-Day Range
$107.62
$120.47
52-Week Range
$77.74
$121.83
Dividend Yield
2.80%
Pfizer stock logo

17. Pfizer NYSE:PFE

$24.53 -0.26 (-1.06%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The current stock price is around $24.74, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Pfizer Inc. reported a significant increase in quarterly earnings, with earnings per share of $0.78, surpassing analysts' expectations, indicating strong financial performance.
  • The company has a solid market capitalization of approximately $140.65 billion, reflecting its stability and presence in the market.

Cons of Pfizer

  • Despite recent earnings growth, the company has a high dividend payout ratio of 91.49%, which may raise concerns about sustainability in the long term.
  • Analysts have mixed ratings, with a significant number assigning a "Hold" rating, indicating uncertainty about future performance.
  • The stock has experienced volatility, with a 12-month low of $20.92, suggesting potential risks for investors looking for stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$139.46 billion
P/E Ratio
13.05
Consensus Rating
Hold
Consensus Price Target
$28.12 (+14.6% Upside)
Volume
33.11 million shares
Average Volume
44.94 million shares
Today's Range
$24.35
$24.78
50-Day Range
$23.27
$25.83
52-Week Range
$20.92
$30.43
Dividend Yield
6.95%
Medtronic stock logo

18. Medtronic NYSE:MDT

$92.87 +0.62 (+0.67%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • The current stock price is around $92.72, which reflects a stable performance in the medical technology sector.
  • Medtronic plc recently reported quarterly earnings that exceeded analyst expectations, indicating strong financial health and operational efficiency.
  • The company has a solid dividend yield of 3.1%, providing a reliable income stream for investors.

Cons of Medtronic

  • The company's dividend payout ratio is currently 78.24%, which may indicate limited room for future dividend increases.
  • Despite recent earnings growth, the stock has a relatively high P/E ratio of 25.54, suggesting it may be overvalued compared to its earnings.
  • Medtronic plc operates in a highly competitive market, which could impact its market share and profitability in the long run.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$119.08 billion
P/E Ratio
25.58
Consensus Rating
Moderate Buy
Consensus Price Target
$102.14 (+10.0% Upside)
Volume
4.53 million shares
Average Volume
7.63 million shares
Today's Range
$91.79
$94.35
50-Day Range
$86.19
$93.23
52-Week Range
$79.29
$96.25
Dividend Yield
3.06%
Sanofi stock logo

19. Sanofi NASDAQ:SNY

$45.22 -4.67 (-9.37%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • Sanofi has received multiple upgrades from analysts, indicating strong confidence in its future performance. Recent upgrades include a shift from "hold" to "buy" and "neutral" to "overweight," suggesting that experts believe the stock is poised for growth.
  • The current stock price is around $49.58, which is below the average target price of $62.00 set by analysts. This presents a potential upside for investors looking for value in their investments.
  • Sanofi reported a significant revenue of $11.34 billion for the latest quarter, exceeding analysts' expectations. This strong performance can indicate robust business operations and market demand for its products.

Cons of Sanofi

  • Sanofi's earnings per share (EPS) for the latest quarter was $0.90, which fell short of the consensus estimate of $0.96. Missing earnings expectations can lead to negative sentiment among investors.
  • The company's revenue decreased by 7.0% year-over-year, which may raise concerns about its growth trajectory and ability to maintain market share in a competitive environment.
  • Despite a strong net margin, the decline in revenue could indicate potential challenges in the market or issues with product demand, which may affect future profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$111.16 billion
P/E Ratio
10.88
Consensus Rating
Buy
Consensus Price Target
$62.00 (+37.1% Upside)
Volume
6.93 million shares
Average Volume
2.56 million shares
Today's Range
$45.07
$46.33
50-Day Range
$45.64
$51.35
52-Week Range
$44.73
$60.12
Dividend Yield
3.22%
Vertex Pharmaceuticals stock logo

20. Vertex Pharmaceuticals NASDAQ:VRTX

$397.12 +0.51 (+0.13%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • The current stock price is around $395, which may present a buying opportunity for investors looking for growth in the biotechnology sector.
  • Vertex Pharmaceuticals has demonstrated strong financial performance, with a recent quarterly revenue increase of over 11% year-over-year, indicating robust demand for its products.
  • The company has a solid market capitalization of approximately $101 billion, reflecting its stability and potential for future growth.

Cons of Vertex Pharmaceuticals

  • The stock has experienced volatility, with a 52-week high of $519 and a low of $362, indicating potential risks associated with price fluctuations.
  • Despite positive earnings, the company operates in a highly competitive biotechnology market, which may impact its market share and profitability.
  • Vertex Pharmaceuticals has a relatively high P/E ratio, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$101.82 billion
P/E Ratio
28.39
Consensus Rating
Moderate Buy
Consensus Price Target
$497.10 (+25.2% Upside)
Volume
654,053 shares
Average Volume
1.64 million shares
Today's Range
$394.75
$400.36
50-Day Range
$366.54
$479.53
52-Week Range
$362.50
$519.88
Dividend Yield
N/A
HCA Healthcare stock logo

21. HCA Healthcare NYSE:HCA

$410.64 +3.03 (+0.74%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The current stock price is around $404, which reflects a strong market capitalization of approximately $94.56 billion, indicating robust investor confidence.
  • HCA Healthcare, Inc. reported impressive quarterly earnings, with earnings per share (EPS) of $6.84, surpassing analyst expectations, which suggests strong operational performance.
  • The company has shown a year-over-year revenue increase of 6.4%, indicating growth potential and resilience in its business model.

Cons of HCA Healthcare

  • The company has a high debt-to-equity ratio of 69.07, which may indicate financial risk and reliance on debt financing, potentially affecting future profitability.
  • HCA Healthcare, Inc. has a negative return on equity of 7,363.11%, which raises concerns about the company's ability to generate profit from shareholders' equity.
  • Recent analyst downgrades, including a shift from "buy" to "neutral" ratings by major firms, may signal caution among investors regarding future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$96.02 billion
P/E Ratio
17.25
Consensus Rating
Moderate Buy
Consensus Price Target
$401.83 (-2.1% Downside)
Volume
1.16 million shares
Average Volume
1.54 million shares
Today's Range
$407.60
$417.20
50-Day Range
$334.26
$410.19
52-Week Range
$289.98
$417.20
Dividend Yield
0.71%
Bristol Myers Squibb stock logo

22. Bristol Myers Squibb NYSE:BMY

$46.73 -0.77 (-1.63%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The current stock price is around $47.38, which may present a buying opportunity for investors looking for value in the biopharmaceutical sector.
  • Recent earnings estimates for FY2027 have been increased to $6.36 per share, indicating positive growth expectations from analysts.
  • Bristol-Myers Squibb has a diverse portfolio of products, including leading treatments like Opdivo and Eliquis, which are well-established in their respective markets.

Cons of Bristol Myers Squibb

  • The company has faced recent downgrades from several analysts, including a reduction in price targets, which may indicate concerns about future performance.
  • With a debt-to-equity ratio of 2.54, Bristol-Myers Squibb has a relatively high level of debt compared to equity, which could pose risks in a rising interest rate environment.
  • Market volatility and economic uncertainties could impact the biopharmaceutical sector, potentially affecting Bristol-Myers Squibb's stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$95.11 billion
P/E Ratio
18.84
Consensus Rating
Hold
Consensus Price Target
$56.38 (+20.6% Upside)
Volume
5.30 million shares
Average Volume
13.07 million shares
Today's Range
$46.31
$47.69
50-Day Range
$43.37
$48.99
52-Week Range
$42.96
$63.33
Dividend Yield
5.26%
CVS Health stock logo

23. CVS Health NYSE:CVS

$73.42 +0.10 (+0.13%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • The company recently reported strong quarterly earnings, exceeding analysts' expectations with earnings per share significantly higher than consensus estimates, indicating robust financial performance.
  • CVS Health Co. has a solid annualized dividend yield of approximately 3.6%, which can provide a steady income stream for investors.
  • The current stock price is around $71, reflecting a stable valuation in the market, which may attract investors looking for growth potential.

Cons of CVS Health

  • The company's dividend payout ratio is relatively high at 74.30%, which may raise concerns about sustainability if earnings do not continue to grow.
  • Despite recent earnings growth, the net margin is only 1.17%, indicating that profitability could be a concern in a competitive market.
  • Insider activity shows a significant sale of shares by a director, which could signal a lack of confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$93.05 billion
P/E Ratio
20.49
Consensus Rating
Buy
Consensus Price Target
$77.94 (+6.2% Upside)
Volume
2.93 million shares
Average Volume
9.63 million shares
Today's Range
$72.91
$73.91
50-Day Range
$58.82
$73.98
52-Week Range
$43.56
$74.53
Dividend Yield
3.64%
McKesson stock logo

24. McKesson NYSE:MCK

$691.33 +0.49 (+0.07%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $720, reflecting strong market interest and potential for growth.
  • McKesson Co. recently reported a significant revenue increase of 23.4% compared to the same quarter last year, indicating robust business performance.
  • The company has a solid dividend yield of 0.5%, with a recent increase in its quarterly dividend from $0.71 to $0.82, showcasing its commitment to returning value to shareholders.

Cons of McKesson

  • The company reported earnings per share (EPS) of $8.26, which missed analysts' consensus estimates, raising concerns about its ability to meet market expectations.
  • McKesson Co. has a negative return on equity of 196.66%, which may indicate inefficiencies in generating profits from shareholders' equity.
  • Insider selling activity has been notable, with insiders selling 62,930 shares valued at over $44 million, which could signal a lack of confidence in the company's short-term performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$85.99 billion
P/E Ratio
27.57
Consensus Rating
Moderate Buy
Consensus Price Target
$725.10 (+4.9% Upside)
Volume
452,140 shares
Average Volume
885,456 shares
Today's Range
$688.37
$696.75
50-Day Range
$658.78
$735.41
52-Week Range
$464.42
$737.89
Dividend Yield
0.41%
Cigna Group stock logo

25. Cigna Group NYSE:CI

$302.07 +3.10 (+1.04%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The current stock price is around $301, which may present a buying opportunity for investors looking for value in the health services sector.
  • The company reported strong quarterly earnings, with earnings per share of $7.20, exceeding analysts' expectations, indicating robust financial health.
  • Revenue for the latest quarter was $67.13 billion, reflecting an 11% increase year-over-year, showcasing growth potential.

Cons of Cigna Group

  • The stock has experienced volatility, with a 52-week high of $370.83 and a low of $256.89, indicating potential risks in price fluctuations.
  • The company's debt-to-equity ratio is 0.65, which, while manageable, suggests a reliance on debt that could pose risks in economic downturns.
  • Despite recent growth, the net margin of 1.92% indicates that profit margins are relatively thin, which could affect long-term profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$80.62 billion
P/E Ratio
16.49
Consensus Rating
Buy
Consensus Price Target
$374.76 (+24.1% Upside)
Volume
899,295 shares
Average Volume
1.83 million shares
Today's Range
$296.28
$303.70
50-Day Range
$262.26
$334.71
52-Week Range
$256.89
$370.83
Dividend Yield
2.01%
GSK stock logo

26. GSK NYSE:GSK

$39.54 +0.19 (+0.47%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $39.50, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • GSK plc recently reported strong quarterly earnings, with earnings per share exceeding analyst expectations, indicating robust financial performance.
  • The company has a solid market capitalization of approximately $80 billion, suggesting stability and a significant presence in the pharmaceutical industry.

Cons of GSK

  • The stock has received a consensus rating of "Reduce" from analysts, suggesting that there may be concerns about its future performance.
  • GSK plc has a relatively high debt-to-equity ratio, which could indicate potential financial risk if the company faces challenges in managing its debt.
  • The company recently cut its dividend, which may signal financial strain or a shift in strategy that could concern income-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$80.54 billion
P/E Ratio
18.31
Consensus Rating
Reduce
Consensus Price Target
$37.38 (-5.5% Downside)
Volume
2.26 million shares
Average Volume
5.08 million shares
Today's Range
$39.18
$39.69
50-Day Range
$36.21
$40.15
52-Week Range
$31.72
$44.19
Dividend Yield
4.24%
Elevance Health stock logo

27. Elevance Health NYSE:ELV

$307.68 -13.92 (-4.33%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$69.24 billion
P/E Ratio
13.08
Consensus Rating
Moderate Buy
Consensus Price Target
$414.75 (+34.8% Upside)
Volume
2.07 million shares
Average Volume
1.97 million shares
Today's Range
$306.38
$313.85
50-Day Range
$274.10
$395.76
52-Week Range
$273.71
$559.95
Dividend Yield
2.15%
Zoetis stock logo

28. Zoetis NYSE:ZTS

$153.45 +1.02 (+0.67%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $156.45, which may present a buying opportunity for investors looking for growth in the animal health sector.
  • Zoetis Inc. reported earnings per share of $1.76, exceeding analysts' expectations, indicating strong financial performance and potential for future growth.
  • The company has a solid net margin of 27.83%, reflecting efficient operations and profitability, which can be attractive to investors seeking stable returns.

Cons of Zoetis

  • Recent target price reductions by analysts, including a downgrade from a "buy" to a "hold" rating, may indicate concerns about the stock's short-term performance.
  • The stock has experienced fluctuations, with a 12-month high of $200.33 and a low of $139.70, suggesting volatility that could deter risk-averse investors.
  • With a P/E ratio of 26.93, the stock may be considered overvalued compared to industry peers, which could limit upside potential for new investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$68.01 billion
P/E Ratio
26.41
Consensus Rating
Moderate Buy
Consensus Price Target
$202.43 (+31.9% Upside)
Volume
986,516 shares
Average Volume
3.05 million shares
Today's Range
$151.35
$153.37
50-Day Range
$145.76
$159.19
52-Week Range
$139.70
$200.33
Dividend Yield
1.28%
Regeneron Pharmaceuticals stock logo

29. Regeneron Pharmaceuticals NASDAQ:REGN

$569.54 +5.74 (+1.02%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The company recently reported strong earnings, with earnings per share significantly exceeding analysts' expectations, indicating robust financial performance.
  • Regeneron Pharmaceuticals, Inc. has a favorable market position, with a consensus rating of "Moderate Buy" from analysts, suggesting positive sentiment towards the stock.
  • The current stock price is around $565, which may present a buying opportunity for investors looking for potential growth.

Cons of Regeneron Pharmaceuticals

  • The stock has experienced fluctuations, with recent trading showing a decline, which may raise concerns about its short-term stability.
  • Despite strong earnings, the company faces competition in the biopharmaceutical sector, which could impact future growth prospects.
  • Analysts have assigned a mix of ratings, including a Sell rating from one analyst, indicating some skepticism about the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$60.36 billion
P/E Ratio
14.35
Consensus Rating
Moderate Buy
Consensus Price Target
$817.67 (+43.6% Upside)
Volume
640,561 shares
Average Volume
1.10 million shares
Today's Range
$559.62
$581.98
50-Day Range
$521.00
$598.16
52-Week Range
$476.49
$1,175.16
Dividend Yield
0.61%
Alnylam Pharmaceuticals stock logo

30. Alnylam Pharmaceuticals NASDAQ:ALNY

$451.34 +3.92 (+0.87%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • Recent upgrades from multiple analysts have significantly increased the target price for Alnylam Pharmaceuticals, Inc., with estimates reaching as high as $550, indicating strong market confidence.
  • The company reported a positive earnings per share (EPS) of $0.32 for the latest quarter, surpassing analysts' expectations, which suggests improving financial health and operational efficiency.
  • Alnylam Pharmaceuticals, Inc. has a strong consensus rating of "Moderate Buy" from analysts, with 22 out of 26 ratings being positive, reflecting a favorable outlook among market experts.

Cons of Alnylam Pharmaceuticals

  • The company has a negative return on equity of 273.52%, which may raise concerns about its ability to generate profit from shareholders' investments.
  • Alnylam Pharmaceuticals, Inc. has a high debt-to-equity ratio of 4.10, indicating that it relies heavily on debt financing, which can be risky if the company faces financial challenges.
  • Insider selling has been significant, with executives selling over 108,000 shares recently, which could signal a lack of confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$59.24 billion
P/E Ratio
-182.97
Consensus Rating
Moderate Buy
Consensus Price Target
$412.79 (-8.5% Downside)
Volume
420,714 shares
Average Volume
958,126 shares
Today's Range
$447.11
$458.30
50-Day Range
$311.12
$467.55
52-Week Range
$205.87
$469.81
Dividend Yield
N/A
Cencora stock logo

31. Cencora NYSE:COR

$292.28 -2.86 (-0.97%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The current stock price is around $291.51, reflecting a strong market presence and potential for growth.
  • Recent analyst upgrades have increased price targets, indicating positive market sentiment and potential for higher returns.
  • Institutional investors hold a significant majority of the stock, suggesting confidence in the company's future performance.

Cons of Cencora

  • Recent insider sales indicate a decrease in ownership, which may raise concerns about the company's short-term outlook.
  • The stock has experienced fluctuations, with a 1-year low of $218.65, suggesting potential volatility that could affect investment returns.
  • Gabelli Funds LLC recently reduced its position in Cencora, which may signal caution among institutional investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$56.59 billion
P/E Ratio
30.03
Consensus Rating
Moderate Buy
Consensus Price Target
$311.25 (+6.5% Upside)
Volume
437,405 shares
Average Volume
1.54 million shares
Today's Range
$291.19
$298.09
50-Day Range
$278.18
$303.36
52-Week Range
$218.65
$309.35
Dividend Yield
0.75%
Becton, Dickinson and Company stock logo

32. Becton, Dickinson and Company NYSE:BDX

$191.02 +1.41 (+0.74%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The current stock price is around $192.84, which may present a buying opportunity for investors looking for growth in the healthcare sector.
  • Recent analyst upgrades, including a shift from a "hold" to a "buy" rating, indicate positive sentiment and potential for stock appreciation.
  • Becton, Dickinson and Company has a strong market capitalization of approximately $55.27 billion, suggesting stability and a solid position in the healthcare market.

Cons of Becton, Dickinson and Company

  • Recent insider selling, including significant transactions by executives, may raise concerns about the company's future performance and insider confidence.
  • The stock has experienced a decrease in ownership percentages among insiders, which could indicate a lack of confidence in the company's short-term prospects.
  • Analysts have mixed ratings, with several maintaining a "hold" rating, suggesting that there may be limited upside potential in the near term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$54.75 billion
P/E Ratio
34.36
Consensus Rating
Hold
Consensus Price Target
$211.44 (+10.7% Upside)
Volume
657,760 shares
Average Volume
2.61 million shares
Today's Range
$187.32
$190.96
50-Day Range
$169.93
$199.50
52-Week Range
$163.33
$251.99
Dividend Yield
2.16%
IDEXX Laboratories stock logo

33. IDEXX Laboratories NASDAQ:IDXX

$640.51 +6.56 (+1.03%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $647, reflecting a strong market position and investor confidence in the company's growth potential.
  • IDEXX Laboratories, Inc. has received multiple upgrades from analysts, with a consensus rating of "Moderate Buy" and a target price of approximately $649.44, indicating positive market sentiment.
  • The company reported impressive earnings, exceeding analysts' expectations with a revenue increase of over 10% year-over-year, showcasing its robust financial health.

Cons of IDEXX Laboratories

  • The stock has a high price-to-earnings (P/E) ratio of 53.88, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling has been significant, with executives selling over 54,000 shares recently, which could signal a lack of confidence in the company's short-term prospects.
  • The company's debt-to-equity ratio of 0.31, while relatively low, suggests that it may not be leveraging debt effectively to fuel growth, which could limit expansion opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$51.24 billion
P/E Ratio
53.33
Consensus Rating
Moderate Buy
Consensus Price Target
$649.44 (+1.4% Upside)
Volume
220,741 shares
Average Volume
705,168 shares
Today's Range
$629.56
$642.47
50-Day Range
$514.61
$682.78
52-Week Range
$356.14
$688.12
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

34. Takeda Pharmaceutical NYSE:TAK

$15.30 +0.16 (+1.02%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is around $14.77, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Takeda Pharmaceutical Company Limited reported earnings per share of $0.52, exceeding analysts' expectations, indicating strong financial performance and potential for growth.
  • The company has a return on equity of 10.50%, suggesting effective management and profitability relative to shareholder equity.

Cons of Takeda Pharmaceutical

  • The company had revenue of $7.45 billion for the last quarter, falling short of analysts' expectations, which may raise concerns about future sales performance.
  • Takeda Pharmaceutical Company Limited was recently downgraded from a "hold" rating to a "strong sell" by Zacks Research, indicating a negative outlook from analysts.
  • The stock has a high P/E ratio of 49.25, which may suggest that it is overvalued compared to its earnings, potentially deterring value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$48.70 billion
P/E Ratio
51.02
Consensus Rating
Hold
Consensus Price Target
N/A
Volume
1.39 million shares
Average Volume
2.55 million shares
Today's Range
$15.21
$15.32
50-Day Range
$13.60
$15.55
52-Week Range
$12.80
$15.56
Dividend Yield
3.68%
Edwards Lifesciences stock logo

35. Edwards Lifesciences NYSE:EW

$80.69 -0.53 (-0.66%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The current stock price is around $81.48, which reflects a strong market position and potential for growth.
  • Recent upgrades from multiple analysts, including a "strong-buy" rating from William Blair, indicate positive market sentiment and confidence in the company's future performance.
  • Analysts have set a consensus target price of approximately $85.90, suggesting potential upside for investors based on current valuations.

Cons of Edwards Lifesciences

  • Insider selling activity has been notable, with recent transactions indicating a decrease in ownership, which may raise concerns about future performance.
  • Despite positive analyst ratings, the stock has experienced fluctuations, and the market can be unpredictable, posing risks for investors.
  • The company has a relatively high price-to-earnings (P/E) ratio of 11.72, which may suggest that the stock is overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.37 billion
P/E Ratio
11.61
Consensus Rating
Moderate Buy
Consensus Price Target
$85.90 (+6.5% Upside)
Volume
1.36 million shares
Average Volume
4.46 million shares
Today's Range
$80.54
$81.57
50-Day Range
$75.68
$81.76
52-Week Range
$64.00
$83.00
Dividend Yield
N/A
argenex stock logo

36. argenex NASDAQ:ARGX

$735.73 +13.72 (+1.90%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The current stock price is around $714, reflecting a strong performance in the market.
  • Institutional investors own over 60% of the company's stock, indicating strong confidence from large financial entities.
  • Recent quarterly earnings exceeded analysts' expectations, showcasing robust financial health with significant revenue growth.

Cons of argenex

  • The stock has shown volatility, with a beta of 0.41, which may indicate a tendency to move less than the market, but could also reflect uncertainty.
  • Despite strong earnings, the high P/E ratio of around 36 suggests that the stock may be overvalued compared to its earnings.
  • Recent price targets from analysts vary significantly, indicating a lack of consensus on the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$45.02 billion
P/E Ratio
37.72
Consensus Rating
Buy
Consensus Price Target
$772.84 (+5.0% Upside)
Volume
430,914 shares
Average Volume
375,912 shares
Today's Range
$729.74
$742.52
50-Day Range
$538.64
$722.01
52-Week Range
$510.05
$742.52
Dividend Yield
N/A
Haleon stock logo

37. Haleon NYSE:HLN

$9.84 -0.06 (-0.56%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The recent increase in the semi-annual dividend to $0.0555 per share indicates a commitment to returning value to shareholders, which can be attractive for income-focused investors.
  • Haleon plc has a relatively low dividend payout ratio of 28.21%, suggesting that the company retains a significant portion of its earnings for reinvestment, which could support future growth.
  • Recent upgrades from multiple analysts, including a "strong-buy" rating from BNP Paribas, reflect positive sentiment and potential for stock price appreciation.

Cons of Haleon

  • The stock's performance has been relatively stagnant, with a 50-day moving average of $9.87 and a 200-day moving average of $10.21, suggesting potential challenges in gaining upward momentum.
  • Despite recent upgrades, there are still mixed ratings from analysts, with some maintaining a "hold" rating, indicating uncertainty about the stock's short-term prospects.
  • Only 6.67% of the stock is owned by hedge funds and other institutional investors, which may suggest a lack of strong institutional support compared to other companies in the sector.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$44.09 billion
P/E Ratio
25.22
Consensus Rating
Moderate Buy
Consensus Price Target
$12.33 (+25.3% Upside)
Volume
5.67 million shares
Average Volume
12.65 million shares
Today's Range
$9.83
$9.95
50-Day Range
$9.28
$10.42
52-Week Range
$8.86
$11.42
Dividend Yield
1.13%
Veeva Systems stock logo

38. Veeva Systems NYSE:VEEV

$268.04 -2.92 (-1.08%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. The company also provides Veeva Development Cloud, a suite of applications for the clinical, regulatory, quality, and safety functions, including Veeva Vault Clinical, Veeva Vault RIM, Veeva Vault Safety, and Veeva Vault Quality; Veeva QualityOne, a quality and document management, and training solution; Veeva RegulatoryOne, a solution that helps companies to manage regulatory submission content; and Veeva Claims addresses the end-to-end product and marketing claims management process. In addition, it offers professional and support services, including implementation and deployment planning and project management; requirements analysis, solution design, and configuration; systems environment management and deployment services; services focused on advancing or transforming business and operating processes related to Veeva solutions; data migration and systems integrations technical consulting services; training on its solutions; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.

Market Capitalization
$43.75 billion
P/E Ratio
54.98
Consensus Rating
Moderate Buy
Consensus Price Target
$299.88 (+11.9% Upside)
Volume
648,077 shares
Average Volume
1.33 million shares
Today's Range
$262.85
$268.68
50-Day Range
$268.85
$295.23
52-Week Range
$200.30
$296.72
Dividend Yield
N/A
ResMed stock logo

39. ResMed NYSE:RMD

$273.08 +3.87 (+1.44%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The current stock price is around $287, reflecting a strong market position and investor confidence in the company's growth potential.
  • ResMed Inc. has a low payout ratio of 25.24%, indicating that the company retains a significant portion of its earnings for reinvestment, which can lead to future growth.
  • Recent analyst upgrades have been positive, with several firms raising their price targets, suggesting strong future performance and investor optimism.

Cons of ResMed

  • Insider selling activity has been notable, with significant shares sold recently, which may raise concerns about the executives' confidence in the company's future performance.
  • Despite positive analyst ratings, there is still a mix of ratings, including a Sell rating from one analyst, indicating potential volatility in investor sentiment.
  • Insiders have sold a total of 27,638 shares valued at over $7 million in the last ninety days, which could signal a lack of confidence in short-term stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$39.96 billion
P/E Ratio
28.70
Consensus Rating
Moderate Buy
Consensus Price Target
$278.36 (+1.9% Upside)
Volume
552,432 shares
Average Volume
1.00 million shares
Today's Range
$267.57
$273.72
50-Day Range
$251.98
$293.48
52-Week Range
$199.92
$293.81
Dividend Yield
0.87%
Alcon stock logo

40. Alcon NYSE:ALC

$78.96 +0.24 (+0.31%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is approximately $91.50, reflecting a strong market position and potential for growth.
  • Alcon Inc. has shown a positive fifty-two week performance, indicating a solid upward trend in its stock value.
  • Institutional ownership is relatively high, suggesting confidence from large investors in the company's future prospects.

Cons of Alcon

  • Despite recent positive trends, the average daily volume has decreased, which could indicate reduced investor interest.
  • The company has experienced fluctuations in short interest, which may suggest uncertainty among investors regarding its future performance.
  • There has been a notable month-to-month change in shares shorted, which could reflect volatility in investor confidence.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$38.96 billion
P/E Ratio
36.74
Consensus Rating
Moderate Buy
Consensus Price Target
$96.06 (+21.6% Upside)
Volume
1.21 million shares
Average Volume
1.70 million shares
Today's Range
$78.34
$79.08
50-Day Range
$78.35
$92.25
52-Week Range
$77.72
$101.10
Dividend Yield
N/A
Humana stock logo

41. Humana NYSE:HUM

$310.54 -1.44 (-0.46%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $303.90, reflecting a strong market position and potential for growth.
  • Humana Inc. reported a revenue increase of 9.6% compared to the same quarter last year, indicating robust business performance.
  • The company has a solid return on equity of 13.67%, showcasing effective management and profitability.

Cons of Humana

  • The company missed earnings expectations by $0.05 in its latest quarterly report, which may raise concerns about future performance.
  • Humana Inc. has a relatively low net margin of 1.28%, suggesting limited profitability compared to its revenue.
  • Recent price target reductions by several analysts indicate a cautious outlook on the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$37.32 billion
P/E Ratio
23.81
Consensus Rating
Hold
Consensus Price Target
$288.14 (-7.2% Downside)
Volume
993,665 shares
Average Volume
1.70 million shares
Today's Range
$308.02
$313.71
50-Day Range
$220.08
$312.22
52-Week Range
$206.87
$375.00
Dividend Yield
1.17%
Agilent Technologies stock logo

42. Agilent Technologies NYSE:A

$128.71 +3.49 (+2.78%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • The current stock price is around $139.25, which reflects a moderate buy consensus from analysts, indicating potential for growth.
  • Agilent Technologies, Inc. reported a revenue increase of over 10% year-over-year, showcasing strong business performance and demand for its solutions.
  • The company has a solid return on equity of 25.51%, suggesting effective management and profitability, which can be attractive to investors looking for strong financial health.

Cons of Agilent Technologies

  • Analysts have recently downgraded target prices, with UBS Group reducing their target from $150.00 to $130.00, which may indicate concerns about future performance.
  • The company has a relatively high price-to-earnings (PE) ratio of 29.33, suggesting that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
  • Despite a strong revenue report, the net margin of 17.97% may raise questions about cost management and profitability compared to industry peers.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.58 billion
P/E Ratio
30.23
Consensus Rating
Moderate Buy
Consensus Price Target
$139.25 (+8.2% Upside)
Volume
1.58 million shares
Average Volume
1.96 million shares
Today's Range
$123.80
$128.72
50-Day Range
$112.12
$125.63
52-Week Range
$96.43
$153.84
Dividend Yield
0.79%
Cardinal Health stock logo

43. Cardinal Health NYSE:CAH

$149.13 -1.43 (-0.95%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The current stock price is around $165.93, which reflects a moderate buy consensus among analysts, indicating potential for growth.
  • Cardinal Health, Inc. has a solid annualized dividend of $2.04, providing a yield of 1.4%, which can be attractive for income-focused investors.
  • The company maintains a low dividend payout ratio of 31.63%, suggesting that it has room to increase dividends in the future while still reinvesting in growth.

Cons of Cardinal Health

  • Recent price target adjustments by analysts, such as a reduction from $200.00 to $190.00, may indicate concerns about the company's near-term performance.
  • Despite a generally positive outlook, some analysts have downgraded their ratings, which could signal potential risks or uncertainties in the market.
  • The healthcare sector can be subject to regulatory changes, which may impact Cardinal Health, Inc.'s operations and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$35.61 billion
P/E Ratio
23.12
Consensus Rating
Moderate Buy
Consensus Price Target
$165.93 (+11.3% Upside)
Volume
1.32 million shares
Average Volume
2.41 million shares
Today's Range
$146.22
$151.38
50-Day Range
$146.18
$167.92
52-Week Range
$106.54
$168.44
Dividend Yield
1.37%
BeOne Medicines stock logo

44. BeOne Medicines NASDAQ:ONC

$319.44 -16.82 (-5.00%)
As of 03:21 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$35.01 billion
P/E Ratio
-184.65
Consensus Rating
Buy
Consensus Price Target
$330.89 (+3.6% Upside)
Volume
229,823 shares
Average Volume
426,977 shares
Today's Range
$316.79
$325.07
50-Day Range
$240.99
$336.26
52-Week Range
$170.99
$339.86
Dividend Yield
N/A
GE HealthCare Technologies stock logo

45. GE HealthCare Technologies NASDAQ:GEHC

$74.03 +1.65 (+2.28%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. More about GE HealthCare Technologies

Pros of GE HealthCare Technologies

  • The current stock price is around $73.73, which may present a buying opportunity for investors looking for value in the healthcare technology sector.
  • Recent earnings reports showed that GE HealthCare Technologies Inc. exceeded analysts' expectations, reporting earnings per share of $1.06, which is a positive indicator of the company's financial health.
  • The company has a strong market capitalization of approximately $33.66 billion, suggesting stability and the potential for growth in the healthcare technology market.

Cons of GE HealthCare Technologies

  • The stock has experienced fluctuations, with a 12-month high of $94.80 and a low of $57.65, indicating potential volatility that could concern risk-averse investors.
  • Recent downgrades from some analysts, including a reduction in price targets, may signal caution regarding the stock's short-term performance.
  • The company has a relatively low dividend yield of 0.2%, which may not attract income-focused investors looking for higher returns from dividends.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.81 billion
P/E Ratio
15.18
Consensus Rating
Moderate Buy
Consensus Price Target
$88.55 (+19.6% Upside)
Volume
1.21 million shares
Average Volume
3.95 million shares
Today's Range
$71.56
$74.06
50-Day Range
$69.85
$77.74
52-Week Range
$57.65
$94.80
Dividend Yield
0.19%
DexCom stock logo

46. DexCom NASDAQ:DXCM

$80.51 +1.59 (+2.01%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. More about DexCom

Pros of DexCom

  • The current stock price is around $75.34, which may present a buying opportunity for investors looking for growth in the medical device sector.
  • Recent analyst upgrades have increased the price target for DexCom, Inc. to $100.00, indicating strong potential for price appreciation.
  • DexCom, Inc. specializes in continuous glucose monitoring systems, a growing market driven by the increasing prevalence of diabetes, which could lead to higher sales and revenue.

Cons of DexCom

  • Insider sales have totaled 15,722 shares worth over $1.3 million in the last quarter, which could signal a lack of confidence among some executives regarding the stock's short-term performance.
  • The stock has experienced a decrease in value, with a noted 9.90% reduction in a director's position, which may raise concerns about the company's current valuation.
  • Despite positive analyst ratings, the stock has a high price-to-earnings ratio of 52.32, suggesting it may be overvalued compared to its earnings, which could deter value-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.55 billion
P/E Ratio
55.88
Consensus Rating
Moderate Buy
Consensus Price Target
$99.89 (+24.1% Upside)
Volume
2.98 million shares
Average Volume
3.92 million shares
Today's Range
$78.68
$81.64
50-Day Range
$74.30
$89.53
52-Week Range
$57.52
$93.25
Dividend Yield
N/A
IQVIA stock logo

47. IQVIA NYSE:IQV

$184.09 -0.53 (-0.28%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The current stock price is around $190, reflecting a strong market position and investor interest.
  • Recent earnings results showed a positive trend, with earnings per share exceeding expectations, indicating robust financial health.
  • Analysts have a consensus rating of "Moderate Buy," suggesting confidence in the company's future performance.

Cons of IQVIA

  • The company has a relatively high debt-to-equity ratio, which may indicate increased financial risk and reliance on borrowed funds.
  • Some analysts have set lower price targets, reflecting concerns about potential market volatility and competition.
  • Insider selling activity has been noted, which could signal a lack of confidence among company executives regarding future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.30 billion
P/E Ratio
26.64
Consensus Rating
Moderate Buy
Consensus Price Target
$229.86 (+24.9% Upside)
Volume
788,424 shares
Average Volume
1.93 million shares
Today's Range
$177.82
$184.69
50-Day Range
$157.53
$201.06
52-Week Range
$134.65
$249.54
Dividend Yield
N/A
Insmed stock logo

48. Insmed NASDAQ:INSM

$142.81 -0.69 (-0.48%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Market Capitalization
$30.18 billion
P/E Ratio
-25.00
Consensus Rating
Moderate Buy
Consensus Price Target
$134.79 (-5.6% Downside)
Volume
995,055 shares
Average Volume
2.80 million shares
Today's Range
$141.25
$145.00
50-Day Range
$96.14
$145.30
52-Week Range
$60.40
$146.84
Dividend Yield
N/A
Koninklijke Philips stock logo

49. Koninklijke Philips NYSE:PHG

$27.70 +0.55 (+2.01%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. More about Koninklijke Philips

Pros of Koninklijke Philips

  • The current stock price is around $27, reflecting a recent increase, which may indicate positive market sentiment towards the company.
  • Recent investments from hedge funds, such as Headlands Technologies LLC and Walleye Capital LLC, suggest growing institutional confidence in Koninklijke Philips.
  • Analysts have given the stock a consensus rating of "Moderate Buy," indicating a generally favorable outlook among market experts.

Cons of Koninklijke Philips

  • The stock has experienced fluctuations, with a 12-month low of around $21.48, which may raise concerns about its volatility.
  • Recent downgrades from analysts, including a shift from a "buy" to a "hold" rating, could signal potential challenges ahead for the company's growth.
  • Despite recent investments, institutional ownership remains at 13.67%, which may indicate a lack of widespread confidence among larger investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$26.67 billion
P/E Ratio
145.76
Consensus Rating
Buy
Consensus Price Target
N/A
Volume
461,980 shares
Average Volume
976,201 shares
Today's Range
$27.35
$27.74
50-Day Range
$23.84
$28.32
52-Week Range
$21.48
$32.91
Dividend Yield
2.98%
Mettler-Toledo International stock logo

50. Mettler-Toledo International NYSE:MTD

$1,288.08 +19.49 (+1.54%)
As of 03:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Mettler-Toledo International Inc manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. More about Mettler-Toledo International

Pros of Mettler-Toledo International

  • The current stock price is around $1,240, which reflects strong market performance and investor confidence in the company's growth potential.
  • Mettler-Toledo International Inc. reported a significant earnings per share (EPS) of $10.09 for the latest quarter, surpassing analyst expectations, indicating robust profitability.
  • The company has shown a revenue increase of 3.9% compared to the same quarter last year, suggesting a positive growth trajectory in its operations.

Cons of Mettler-Toledo International

  • The company has a high price-to-earnings (P/E) ratio of 32.99, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • Mettler-Toledo International Inc. has a negative return on equity of 476.07%, suggesting that the company is not effectively generating profit from its equity, which could raise concerns for investors.
  • Insider selling has been observed, with significant shares sold recently, which may indicate a lack of confidence from those closest to the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$26.53 billion
P/E Ratio
32.62
Consensus Rating
Moderate Buy
Consensus Price Target
$1,311.11 (+1.8% Upside)
Volume
55,574 shares
Average Volume
171,372 shares
Today's Range
$1,249.13
$1,287.09
50-Day Range
$1,165.30
$1,324.30
52-Week Range
$946.69
$1,521.01
Dividend Yield
N/A